Chiral Carbon Nanodots Modulate α‐Synuclein Homeostasis to Combat Parkinson's Disease DOI

Y. L. Han,

Yuqi Zhang, Jiahao Huang

и другие.

Small Methods, Год журнала: 2025, Номер unknown

Опубликована: Май 15, 2025

Abstract Inhibiting α‐synuclein (α‐syn) aggregation is an effective treatment for Parkinson's disease (PD), and chiral recognition of proteins offers a novel strategy designing efficient inhibitors. However, the impact selectivity on α‐syn its regulatory mechanisms remain ambiguous. In this work, it synthesized carbon nanodots (CNDs), including L‐CNDs, D‐CNDs, DL‐CNDs, found that D‐CNDs exhibited most potent inhibitory effect aggregation. ¹H‐¹⁵N heteronuclear single quantum coherence nuclear magnetic resonance spectroscopy revealed CNDs primarily interact with through electrostatic interactions, specifically targeting key aggregation‐prone residues, thereby disrupting β‐sheet formation reducing fibril assembly. contrast, L‐CNDs DL‐CNDs limited effects, attributed to their weak affinity non‐amyloid‐β component region. Moreover, efficiently crossed blood‐brain barrier, significantly reduced accumulation, alleviated neuronal damage, ameliorated cognitive function. This work underlines critical role chirality in modulating provides developing enantiomer‐selective inhibitors PD therapy.

Язык: Английский

Exosomes as Biomarkers and Therapeutic Agents in Neurodegenerative Diseases: Current Insights and Future Directions DOI Creative Commons

Sam Dehghani,

Ozgecan Ocakcı,

Pars Tan Hatipoglu

и другие.

Molecular Neurobiology, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Abstract Neurodegenerative diseases (NDs) like Alzheimer’s, Parkinson’s, and ALS rank among the most challenging global health issues, marked by substantial obstacles in early diagnosis effective treatment. Current diagnostic techniques frequently demonstrate inadequate sensitivity specificity, whilst conventional treatment strategies encounter challenges related to restricted bioavailability insufficient blood–brain barrier (BBB) permeability. Recently, exosomes—nanoscale vesicles packed with proteins, RNAs, lipids—have emerged as promising agents potential reshape therapeutic approaches these diseases. Unlike drug carriers, they naturally traverse BBB can deliver bioactive molecules affected neural cells. Their molecular cargo influence cell signaling, reduce neuroinflammation, potentially slow neurodegenerative progression. Moreover, exosomes serve non-invasive biomarkers, enabling precise while allowing real-time disease monitoring. Additionally, engineered exosomes, loaded molecules, enhance this capability targeting diseased neurons overcoming barriers. By offering enhanced reduced immunogenicity, an ability bypass physiological limitations, exosome-based present a transformative advantage over existing approaches. This review examines multifaceted role of NDDs, emphasizing their capabilities, intrinsic functions, advanced vehicles.

Язык: Английский

Процитировано

1
Chiral Carbon Nanodots Modulate α‐Synuclein Homeostasis to Combat Parkinson's Disease DOI

Y. L. Han,

Yuqi Zhang, Jiahao Huang

и другие.

Small Methods, Год журнала: 2025, Номер unknown

Опубликована: Май 15, 2025

Abstract Inhibiting α‐synuclein (α‐syn) aggregation is an effective treatment for Parkinson's disease (PD), and chiral recognition of proteins offers a novel strategy designing efficient inhibitors. However, the impact selectivity on α‐syn its regulatory mechanisms remain ambiguous. In this work, it synthesized carbon nanodots (CNDs), including L‐CNDs, D‐CNDs, DL‐CNDs, found that D‐CNDs exhibited most potent inhibitory effect aggregation. ¹H‐¹⁵N heteronuclear single quantum coherence nuclear magnetic resonance spectroscopy revealed CNDs primarily interact with through electrostatic interactions, specifically targeting key aggregation‐prone residues, thereby disrupting β‐sheet formation reducing fibril assembly. contrast, L‐CNDs DL‐CNDs limited effects, attributed to their weak affinity non‐amyloid‐β component region. Moreover, efficiently crossed blood‐brain barrier, significantly reduced accumulation, alleviated neuronal damage, ameliorated cognitive function. This work underlines critical role chirality in modulating provides developing enantiomer‐selective inhibitors PD therapy.

Язык: Английский

Процитировано

0